Methylnaltrexone

Drugs

Volumn 70, Issue 7, 2010, Pages 919-928

  Garnock Jones, Karly P ^a   McKeage, Kate ^a  

^a Wolters Kluwer Health   (New Zealand)

Author keywords

Adis Drug Profiles; Constipation; Methylnaltrexone bromide, general; Opioid analgesics, adverse reactions; Palliative care

Indexed keywords

17 METHYLNALTREXONE; 17 METHYLNALTREXONE BROMIDE; MU OPIATE RECEPTOR; OPIATE; PLACEBO;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ASTHENIA; BLOOD BRAIN BARRIER; BODY TEMPERATURE; CLINICAL TRIAL; CONSTIPATION; CRITICAL ILLNESS; DELIRIUM; DIARRHEA; DIZZINESS; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG STRUCTURE; FLATULENCE; FLUSHING; HUMAN; LETHARGY; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PAIN; PERIPHERAL EDEMA; QT INTERVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANALGESICS, OPIOID; CONSTIPATION; HUMANS; MOLECULAR STRUCTURE; NALTREXONE; QUATERNARY AMMONIUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME;

EID: 77951702626     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204520-000000000-00000     Document Type: Review

References (33)

1. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pa-thophysiology and potential new therapies. Drugs 2003; 63 (7): 649-671
2. Yuan CS. Methylnaltrexone mechanisms of action and ef-fects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007 Jun; 41 (6): 984-993
3. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007 Nov 1; 34 (5): 547-565
4. Quigley C. The role of opioids in cancer pain. BMJ 2005 Oct 8; 331 (7520): 825-829
5. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004 Dec; 112 (3): 372-380
6. Chappell D, Rehm M, Conzen P. Opioid-induced constipa-tion in intensive care patients: relief in sight? Crit Care 2008; 12 (4): 161
7. National Health Service Scotland. Constipation in palliative care [online]. Available from URL: http://www.palliative careguidelines.scot.nhs.uk/ documents/Constipationfinal.pdf [Accessed 2010 Apr 13]
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: palliative care. V.1.2010 [online]. Available from URL: http://www.nccn.org/professionals/physician-gls/PDF/palliative.pdf [Accessed 2010 Apr 13]
9. Wyeth Pharmaceuticals Inc. Relistor® (methylnaltrexone bromide) subcutaneous injection: US prescribing information [online]. Available from URL: http://www.wyeth. com/content/showlabeling.asp?id=499 [Accessed 2010 Apr 13]
10. Yuan CS, Foss JF. Gastric effects of methylnaltrexone on jx, K, and d opioid agonists induced brainstem unitary responses. Neuropharmacology 1999 Mar; 38 (3): 425-432
11. Valentino RJ, Herling S, Woods JH, et al. Quaternary naltrexone: evidence for the central mediation of discriminative stimulus effects of narcotic agonists and antagonists. J Pharmacol Exp Ther 1981 Jun; 217 (3): 652-659
12. van Hoogmoed LM, Boscan PL. In vitro evaluation of the effect of the opioid antagonist N-methylnaltrexone on motility of the equine jejunum and pelvic flexure. Equine Vet J 2005 Jul; 37 (4): 325-328
13. Yuan CS, Foss JF, Moss J. Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur J Pharmacol 1995 Mar 24; 276 (1-2): 107-111
14. Gmerek DE, Cowan A, Woods JH. Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther 1986 Jan; 236 (1): 8-13
15. Bianchi G, Fiocchi R, Tavani A, et al. Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity. Life Sci 1982 May 31; 30 (22): 1875-1883
16. Walker MJ, Le AD, Poulos CX, et al. Role of central versus peripheral opioid receptors in analgesia induced by repeated administration of opioid antagonists. Psychopharmacol-ogy (Berl) 1991; 104 (2): 164-166
17. Russell J, Bass P, Goldberg LI, et al. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982 Mar 12; 78 (3): 255-261
18. Yuan CS, Wei G, Foss JF, et al. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 2002 Jan; 300 (1): 118-123
19. Yuan CS, Foss JF, Osinski J, et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997 Apr; 61 (4): 467-475
20. Murphy DB, Sutton JA, Prescott LF, et al. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 1997 Oct; 87 (4): 765-770
21. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996 Apr; 59 (4): 469-475
22. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000 Jan 19; 283 (3): 367-372
23. Yuan CS, Foss JF, O'Connor M, et al. Effects of intra-venous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic me-thadone therapy: a pilot study. Pain 1999 Dec; 83 (3): 631-635
24. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009 Jan-Feb; 7 (1): 39-46
25. Thomas J, Karver S, Austin Cooney G, et al. Methylnal-trexone for opioid-induced constipation in advanced illness. N Engl J Med 2008 May 29; 358 (22): 2332-2343
26. European Medicines Agency. Relistor® (methylnaltrexone bromide solution) EU prescibing information [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/relistor/emea-combined-h870en.pdf [Accessed 2010 Apr 13]
27. Wang CZ, Li XL, Sun S, et al. Methylnaltrexone, a periph-erally acting opioid receptor antagonist, enhances tumor-icidal effects of 5-Fu on human carcinoma cells. Anticancer Res 2009 Aug; 29 (8): 2927-2932
28. Singleton PA, Mambetsariev N, Lennon FE, et al. Methyl-naltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res 2010; 2 (1): 5
29. Singleton PA, Garcia JG, Moss J. Synergistic effects of me-thylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 2008 Jun; 7 (6): 1669-1679
30. Yuan CS, Sun S, Attele A, et al. Methylnaltrexone potenti-ates body weight and fat reduction with leptin. J Opioid Manag 2009 Nov 31; 5 (6): 373-378
31. Yuan CS, Wang CZ, Attele A, et al. Methylnaltrexone re-duced body weight gain in ob/ob mice. J Opioid Manag 2009 Jul 31; 5 (4): 213-218
32. Portenoy RK, Thomas J, Boatwright MLM, et al. Sub-cutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008 May 1; 35 (5): 458-468
33. Chamberlain BH, Cross K, Winston JL, et al. Methylnal-trexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage 2009 Nov; 38 (5): 683-690